Metronomic low-dose chemotherapy as antiangiogenic therapeutic strategy for cancer

Area of Science:

• Oncology
• Cancer Biology
• Pharmacology

Background:

• Angiogenesis, or new blood vessel formation, is crucial for tumor growth and metastasis.
• Angiogenesis inhibitors are explored for antitumor activity.
• Conventional cytotoxic agents may possess antiangiogenic properties at low doses.

Purpose of the Study:

• To explore the antiangiogenic potential of metronomic chemotherapy.
• To evaluate the efficacy and toxicity of metronomic chemotherapy, alone and in combination with angiogenesis inhibitors.
• To assess the potential of metronomic chemotherapy in managing cancer as a chronic disease.

Main Methods:

• Preclinical studies investigating low-dose, frequent administration of cytotoxic agents (metronomic chemotherapy).
• Evaluation of combined regimens of metronomic chemotherapy and specific angiogenesis inhibitors.
• Assessment of therapeutic efficacy and toxicity in various tumor models.

Main Results:

• Metronomic chemotherapy demonstrates significant therapeutic antitumor efficacy.
• This scheduling exhibits very limited toxicity compared to conventional chemotherapy.
• Combining metronomic chemotherapy with angiogenesis inhibitors further enhances antitumor activity.

Conclusions:

• Metronomic chemotherapy offers a promising strategy with reduced toxicity.
• Combination therapy with angiogenesis inhibitors may improve clinical outcomes and survival.
• This approach holds potential for long-term cancer management, shifting the paradigm towards a chronic disease model.